Psychedelic Stock News

Numinus Announces Listing of New Warrants

Numinus announces the listing of its latest series of warrants for public trading, under the symbol "NUMI.WS". Warrants have an exercise price of CAD$0.90 and are valid until December 29, 2022.

TSI EDITOR | 2021-01-22

Mind Cure Health Inc. Announces an Increase to Previously Announced Bought Deal Public Offering

Mind Cure has upsized its bought deal financing by DOUBLE to CAD$20 million.

TSI EDITOR | 2021-01-22

Beckley Foundation: The Major Psychedelics Non-Profit Across The Pond

The UK-based Beckley Foundation is a psychedelics non-profit founded over 20 years ago that is having an increasing impact on the Psychedelics Revolution.

TSI EDITOR | 2021-01-22

MCUR’s $10 Million Financing Triples Cash Reserves, Powers Operations Strategies

Mind Cure announces a CAD$10 million bought deal financing at a unit price of CAD$0.60. Proceeds will be directed toward product research development and related tech initiatives like its iSTRYM digital therapeutics platform.

TSI EDITOR | 2021-01-21

MindMed Announces the Start of the First-Ever Clinical Trial Combining MDMA and LSD

MindMed begins the first Phase 1 clinical trial testing the safety and tolerance of MDMA and LSD in combination.

TSI EDITOR | 2021-01-20

Entheon Biomedical Partners with Divergence Neuro Technologies Inc. for Predictive Biomarker Platform Development

Entheon announces a new partnership to advance its psychedelic drug R&D.

TSI EDITOR | 2021-01-19

CYBIN Announces Upsize to Previously Announced Bought Deal Offering

Cybin's bought deal financing has been upsized to CAD$30 million.

TSI EDITOR | 2021-01-19

Low Tide For Psychedelic Stocks With Media, Investors Distracted

The U.S. election has become a major political circus. With investors distracted and the media focused elsewhere, psychedelic stocks are temporarily at low tide.

TSI EDITOR | 2021-01-19